In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 EMAIL TO FRIEND     |      PRINTER FRIENDLY     |    
          advertisement

FDA Approves Avastin for Most Common Kidney Cancer

Aug. 4 (HealthDay News) -- The drug Avastin has been approved in the United States for treating people with metastatic renal cell carcinoma, the most common form of kidney cancer.

The U.S. Food and Drug Administration approved Avastin to be used in combination with the drug interferon-alpha, Agence France Presse reported.

A study found that people treated with a combination of the drugs lived nearly twice as long without disease progression compared to people treated with only interferon-alpha.

Since the end of 2007, Avastin has been available in Europe as a first-line treatment for advanced kidney cancer, AFP reported. Last week, European officials approved the drug for treatment of breast cancer.


advertisement

Advice from Dr. Nancy Snyderman

Dr. Nancy Snyderman

Helpful tips and information on weight loss

Get answers from an expert
advertisement

YourTotalHealth      

Home  |  Health Centers  |  Health A-Z  |  Staying Healthy  |  Diet & Fitness  |  Woman & Family  |  Pregnancy  |  Community  |  

also on iVillage: Pregnancy & Parenting  |  Beauty & Style  |  Home & Garden  |  Food  |  Weddings  |  Love  |  Entertainment  |  NeverSayDiet

Terms of Service  |  Privacy Policy  |  Site Map  |  Newsletters  |  Feedback

Copyright (c) 2000-2009 iVillage Inc. All rights reserved. The information provided on this site is intended for your general knowledge only and is not a substitute for professional medical advice or treatment for specific medical conditions. You should not use this information to diagnose or treat a health problem or disease without consulting with a qualified healthcare provider. Please consult your healthcare provider with any questions or concerns you may have regarding your condition.